

## REFERENCES

1. Monk, J.P., and Todd, P.A. Bezafibrate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hyperlipidaemia. Drugs 33(1987): 539-576.
2. Grundy, S.M., and Vega, G.L. Fibric acids. Effects on lipids and lipoprotein metabolism. Am.J.Med. 83 Suppl. 5B(1987): 9-20.
3. Arntz, H.R., et al. Effects of bezafibrate and clofibrate on blood rheology and lipoproteins in primary hyperlipoproteinaemia. Clin.Trials J. 18(1981): 280-286.
4. Consensus Conference. Lowering blood cholesterol to prevent coronary heart disease. JAMA 253 (1985): 2080-2086.
5. Malloy, M.J., and Kane, J.P. Agents used in hyperlipidemia. In B.G. Katzung (ed.), Basic & clinical pharmacology, pp.477-490. Connecticut: Appleton & Lange, 1992.
6. Dart, A.M. Managing elevated blood lipid concentrations: Who, when and how? Drugs 39 (1990) : 374-387.
7. Stahlberg, D. Effects of bezafibrate- a hypolipidemic drug. Cardiovascular Drugs Reviews 10 (1992): 259-279.

8. Denke, M.A., and Grundy, S.M. Treatment of diabetic dyslipidaemia. 627<sup>th</sup> Meeting of the Biochemical Society Transactions 17(1989): 56-58.
9. Olsson, A.G., and Lang, P.D. Dose-response study of bezafibrate on serum lipoprotein concentrations in hyperlipoproteinaemia. Atherosclerosis 31 (1978): 421-428.
10. Bradford, R.H., Goldberg, A.C., Schonfeld, G., and Knopp, R.H. Double-blind comparison of bezafibrate versus placebo in male volunteers with hyperlipoproteinemia. Atherosclerosis 92 (1992): 31-40.
11. Olsson, A.G., Lang, P.D., and Vollmar, J. Effect of bezafibrate during 4.5 years of treatment of hyperlipoproteinaemia. Atherosclerosis 55 (1985):195-202.
12. Heller, F., and Harvengt, C. Effects of clofibrate, bezafibrate, fenofibrate and probucol on plasma lipolytic enzymes in normolipaemic subjects. Eur.J.Clin.Pharmacol. 25(1983): 57-63.
13. Brown, M.S., and Goldstein, J.L. Drugs used in the treatment of hyperlipoproteinemias. In A.G. Gilman, T.W. Rall, A.S. Nies, and P.Taylor (eds.), Goodman and Gilman's the pharmacological basis of therapeutics, pp. 874-896. New York: Pergamon Press, 1990.

14. Stewart, J.M., Packard, C.J., Lorimer, A.R., Boag, D.E., and Sheperd, J. Effects of bezafibrate on receptor-mediated and receptor-independent low density lipoprotein catabolism in type II hyperlipoproteinaemic subjects. Atherosclerosis 44(1982):355-365.
15. Abshagen, U., et al. Disposition pharmacokinetics of bezafibrate in man. Eur.J.Clin.Pharmacol. 16(1979): 31-38.
16. Abshagen, U., Sporl-Radun, S., and Marinow, J. Steady-state kinetics of bezafibrate and clofibrate in healthy female volunteers. Eur.J.Clin.Pharmacol. 17(1980): 305-308.
17. Hebold, G., et al. Toxicological, teratological, fertility, mutagenicity, and carcinogenicity investigations with bezafibrate in animals. In H. Greten, P.D. Lang, and G. Schettler (eds.), Lipoproteins and coronary heart disease, pp.61-63. New York: Witzstrock Publishing House, 1980.
18. Fahimi, H.D., et al. The short - and long - term effects of bezafibrate in the rat. Ann.NY.Acad.Sci. 386 (1982): 111-135.
19. Makowska, J.M., Bonner, F.W., and Gibson, G.G. Hepatic induction potency of hypolipidaemic drugs in the rat following long-term administration: influence of different dosing regimens. Xenobiotica 20(November 1990): 1121-1128.

20. Eacho, P.I., and Foxworthy, P.S. Inhibition of hepatic fatty acid oxidation by bezafibrate and bezafibroyl CoA. Biochem. Biophys. Res. Commun. 157 (December 1988) :1148-1153.
21. Vance, D.E. Metabolism of fatty acids. In G.Zubay(ed.), Biochemistry, pp. 444-471. United States of America: Wm.C.Brown Communications, Inc., 1993.
22. Kamonwan Prapassiripan. Effects of gemfibrozil on the functions of isolated rat liver mitochondria. Master's Thesis Chulalongkorn University, 1993.
23. Beil, F.U., et al. Lovastatin versus bezafibrate : efficacy, tolerability, and effect on urinary mevalonate. Cardiology 77(Suppl 4) (1990) :22-32.
24. Olsson, A.G., et al. Effect of BM 15075 on lipoprotein concentrations in different types of hyperlipoproteinaemia. Atherosclerosis 27 (1977): 279-287.
25. De Robertis, E.D.P., and De Robertis, E.M.F. Mitochondria and oxidative phosphorylation. In, Cell and Molecular biology, pp. 291-324. Hong Kong: Info-Med limited, 1988.
26. Olson, M.S. Bioenergetics and oxidative metabolism. In T.M.Devlin (ed.), Textbook of biochemistry with clinical correlations, pp.255-324. New York: A Wiley Medical Publication, 1982.

27. Rawn, J.D. Oxidative phosphorylation. In, Biochemistry, pp.359-383. North Carolina: Carolina Biological Supply Company, 1989.
28. Avers, C.J. Mitochondria. In, Molecular cell biology, pp.305-361. California: The Benjamin/ Cumming. Publishing Company, 1986.
29. Darnell, J., Lodish, H., and Baltimore, D. Energy conversion: the formation of ATP in chloroplasts, mitochondria, and bacteria. In, Molecular cell biology, pp.859-910. New York : Scientific American Books, Inc., 1986.
30. Parson, W.W. Electron Transport and oxidative phosphorylation. In G.Zubay (ed.), Biochemistry, pp.379-413. United States of America: Wm. C. Brown Communications, Inc., 1993.
31. Hatefi, Y. The mitochondrial electron transport and oxidative phosphorylation system. Ann. Rev. Biochem. 54(1985):1015-1069.
32. Hogeboom, G.H. Fractionation of cell components of animal tissues. In S.P. Colowick, and N.O. Kaplan (eds.), Methods in enzymology. Vol.1 pp.16-19. New York: Academic Press, 1955.
33. Myers, D.K., and Slater, E.C. The enzymic hydrolysis of adenosine triphosphate by liver mitochondria. I. Activities at different pH values. Biochem.J. 67(1957): 558-572.

34. Sordahl, L.A., et al. Methods in pharmacology In A. Schwartz (ed.), pp.247-286. New York: Merdith Corporation, 1971.
35. Fowler, B.A., Lucier, G.W., and Hayes, A.W. Principles and methods of toxicology In A.W. Hayes (ed.) pp.635-658 New York: Raven Press, 1982.
36. Chance, E., and Williams, G.R. The respiratory chain and oxidative phosphorylation. Advances Enzymology 17(1956): 65-134.
37. Estabrook, R.W. Mitochondrial respiratory control and the polarographic measurement of ADP: O ratios. In S.P. Colowick, and N.O. Kaplan (eds.), Method in enzymology, Vol.10 pp.41-47. New York: Academic Press, 1967.
38. Weinbach, E.C. Pentachlorophenol and mitochondrial adenosinetriphosphatase. J.Biol.Chem. 221 (1956): 609-618.
39. Bertina, R.M., and Slater, E.C. The effects of phosphate and electron transport on the carbonyl cyanide m-chlorophenyl hydrazone-induced ATPase of rat liver mitochondria. Biochim.Biophys.Acta. 376 (1975): 492-504.
40. Fiske, O.H., and Subbarow, Y. The colorimetric determination of phosphorus. J. Biol. Chem. 66 (1925):375-400.

41. Lowry, O.H., Rosebrough, N.J., Farr, A.L., and Randall, R.J. Protein measurement with Folin Phenol Reagent. J. Biol. Chem. 193 (1951): 265-275.
42. Miller, G.L. Protein determination for large number of samples. Anal. Chem. 31 (1959): 964.
43. Chudapongse, P., and Janthasoot, W. Mechanism of the inhibitory action of capsaicin on energy metabolism by rat liver mitochondria. Biochem. Pharmacol. 30 (1981): 735-740.
44. Reanmongkol, W., Janthasoot, W., Wattanatorn, W., Dhumma-Upakorn, P., and Chudapongse, P. Effects of piperine on bioenergetic functions of isolated rat liver mitochondria. Biochem. Pharmacol. 37 (1988): 753-757.
45. Nuttasiri Saeyib. Inhibition of energy-linked functions of isolated rat liver mitochondria by amiodarone. Master's Thesis Chulalongkorn University, 1992.
46. Godinot, C., Gautheron, D.C., Galante, Y., and Hatefi, Y. Labelling of thiols involved in the activity of complex V of the mitochondrial oxidative phosphorylation system. J. Biol. Chem. 256(1981): 6776-6782.
47. Le-quoc, K., and Le-quoc, D. Control of the mitochondrial inner membrane permeability by sulfhydryl groups. Arch. Biochem. Biophys. 216 (1982): 631-651.

48. Robillard, G.T., and Konings, W.N. A hypothesis for the role of dithiol-disulfide interchange in solute transport and energy-transducing processes. Eur. J. Biochem. 127 (1982): 597-604.
49. Cleland, W.W. Dithiothreitol, a new protective reagent for SH group. Biochemistry 3 (1964): 480-482.
50. Gunter, T.E., and Pfeiffer, D.R. Mechanisms by which mitochondria transport calcium. Invited review (1990): C755-C786.
51. Carafoli, E. Intracellular calcium homeostasis. Ann. Rev. Biochem. 56 (1987): 395-433.
52. Vasington, F.D., Gazzotti, P., Tiozzo, R., and Carafoli, E. The effect of ruthenium red on  $\text{Ca}^{2+}$  transport and respiration in rat liver mitochondria. Biochim. Biophys. Acta. 256 (1972): 43-54.
53. Wingrove, D.E., and Gunter, T.E. Kinetics of mitochondrial calcium transport II. A kinetic description of the sodium-dependent calcium efflux mechanism of liver mitochondria and inhibition by ruthenium red and by tetraphenylphosphonium. J. Biol. Chem. 261 (1986):15166-15171.
54. Crompton, M., Capano, M., and Carafoli, E. The sodium-induced efflux of calcium from heart mitochondria. A possible mechanism for the regulation of mitochondrial calcium. Eur. J. Biochem. 69 (1976): 453-462.



55. Puskin, J.S., Gunter, T.E., Gunter, K.K., and Russel, P.R. Evidence for more than one  $\text{Ca}^{2+}$  transport mechanism in mitochondria. Biochemistry 15 (1976): 3834-3842.
56. Crompton, M., Moser, R., Lodi, H., and Carafoli, E. The interrelations between the transport of sodium and calcium in mitochondria of various mammalian tissues. Eur. J. Biochem. 82 (1978): 25-31.
57. Beatrice, M.C., Palmer, J.W., and Pfeiffer, D.R. The relationship between mitochondrial membrane permeability, membrane potential, and the retention of  $\text{Ca}^{2+}$  by mitochondria. J. Biol. Chem. 255(1980): 8663-8671.
58. Haworth, R.A., and Hunter, D.R. Allosteric inhibition of the  $\text{Ca}^{2+}$ -activated hydrophilic channel of the mitochondrial inner membrane by nucleotides. J. Membr. Biol. 54(1980) :231-236.
59. Pfeiffer, D.R., Schmid, P.C., Beatrice, M.C., and Schmid, H.H.O. Intramitochondrial phospholipase activity and the effects of  $\text{Ca}^{2+}$  plus N-ethylmaleimide on mitochondrial function. J. Biol. Chem. 254(1979):11485-11494.
60. Hunninghake, D.B., and Peters, J.R. Effect of fibric acid derivatives on blood lipid and lipoprotein levels. Am. J. Med. 83 (1987): 44-49.

61. Illingworth, D.R. Lipid-lowering drugs. An overview of indications and optimum therapeutic use. Drugs 33 (1987): 259-279.
62. Heytler, P.G. Uncouplers of oxidative phosphorylation. In M. Erecinska, and D.F. Wilson (eds), Inhibitors of mitochondrial functions. pp.199-210. Oxford: Pergamon Press, 1981.
63. Terada, H. The interaction of highly active uncouplers with mitochondria. Biochim. Biophys. Acta. 639 (1981): 225-242.
64. Nicotera, P., Bellomo, G., and Orrenius, S. Calcium - mediated mechanisms in chemically induced cell death. Annu. Rev. Pharmacol. Toxicol. 32 (1992): 449-470.
65. Bosch, H. Van den, Schutgens, R.B.H., Wanders, R.J.A., and Tager, J.M. Biochemistry of peroxisomes. Annu. Rev. Biochem. 61(1992): 157-197.

4135

## VITAE

Mrs. Preeyaron Tresukosol was born in Bangkok on September 24, 1963. She received her Bachelor Degree in Pharmacy from Faculty of Pharmaceutical Science, Chulalongkorn University in 1986 and has been a pharmacist in the Veterans General Hospital since 1988. She has married with Mr. Rittanan Tresukosol in 1991 and, a year later, came to study for her Master's degree in Pharmacy at Chulalongkorn University.